Recruiting
Assessment of Geriatric Evaluations Impact on New AML Guidance (AGE-ING)
AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study
- Sponsor
- Abramson Cancer Center at Penn Medicine (Academic or other)
- Enrolment
- 100 planned
- Conditions
- AML, Adult
- Ages
- adults, older adults
- Registry
- NCT05909501
From the registry
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
Primary outcomes
- Evaluate physiologic age using baseline measures of physical function, depression, cognition, frailty, and PROs in newly diagnosed AML patients receiving intensive and non-intensive treatment in relation to overall survival at 1 year.
- Evaluate baseline measures of physiologic age in relation to short term mortality
- Evaluate baseline measures of physiologic age in relation to grade 3, 4, and 5 toxicities from treatment
- Evaluate baseline measures of physiologic age in relation to complete remission